{"id":"NCT01774344","sponsor":"Bayer","briefTitle":"Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma","officialTitle":"A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05-14","primaryCompletion":"2016-02-29","completion":"2019-07-05","firstPosted":"2013-01-24","resultsPosted":"2017-06-05","lastUpdate":"2020-08-20"},"enrollment":573,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Hepatocellular"],"interventions":[{"type":"DRUG","name":"Regorafenib (Stivarga, BAY73-4506)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Regorafenib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study was to evaluate efficacy and safety of regorafenib in patients with advanced liver cancer who had progressed after sorafenib treatment. Patients were treated with regorafenib or placebo using a 2:1 randomization scheme.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From randomization (Day 1) of the first subject until 419 days later","effectByArm":[{"arm":"Placebo","deltaMin":237,"sd":192},{"arm":"Regorafenib 160 mg (BAY73-4506)","deltaMin":323,"sd":276}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.000017"},{"comp":"OG000 vs OG001","p":"= 0.000149"},{"comp":"OG000 vs OG001","p":"= 0.000107"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":11},"locations":{"siteCount":147,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","China","Czechia","France","Germany","Hungary","Italy","Japan","Netherlands","Russia","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["29704513","27932229","40388796","30738047"],"seeAlso":["https://www.clinicaltrialsregister.eu/","http://clinicaltrials.bayer.com/"]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":193},"commonTop":["Palmar-plantar erythrodysaesthesia syndrome","Diarrhoea","Fatigue","Decreased appetite","Aspartate aminotransferase increased"]}}